Perspectives in the treatment of pancreatic adenocarcinoma

Table 2 Controlled trials in adjuvant chemotherapy for pancreatic ductal adenocarcinoma

Study name	No. of patients enrolled	Regimen	Survival rate	P value	Ref.
CONKO-001	368	Gemcitabine	20.7% (5 yr)	0.01	[145]
		Observation	10.4% (5 yr)
ESPAC-3	1088	Gemcitabine	23.6 mo	0.39	[146]
		5-FU + Leucovorin	23.0 mo
JASPAC 01	385	Gemcitabine	53%	0.0001	[64]
		S-1	70%

CONKO-001: Charité Onkologie 001; ESPAC-3: European Study Group for Pancreatic Cancer 3; JASPAC 01: Japan Adjuvant Study Group of Pancreatic Cancer 01; 5-FU: 5-fluoruracil.